BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17409954)

  • 1. Novel cytotoxic agents for non-small cell lung cancer.
    Edelman MJ
    J Thorac Oncol; 2006 Sep; 1(7):752-5. PubMed ID: 17409954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer.
    Edelman MJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S30-4. PubMed ID: 19362944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel taxanes/epothilones.
    Dy G
    J Thorac Oncol; 2010 Dec; 5(12 Suppl 6):S490-1. PubMed ID: 21102252
    [No Abstract]   [Full Text] [Related]  

  • 4. Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance.
    Edelman MJ; Shvartsbeyn M
    Clin Lung Cancer; 2012 May; 13(3):171-80. PubMed ID: 22133291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in chemotherapy for advanced non-small cell lung cancer.
    Raez LE; Lilenbaum R
    Curr Opin Oncol; 2006 Mar; 18(2):156-61. PubMed ID: 16462185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
    Alberti C
    Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel anti-tubulin cytotoxic agents for breast cancer.
    Morris PG; Fornier MN
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):175-85. PubMed ID: 19192956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors.
    Wakelee HA; Sikic BI
    Clin Lung Cancer; 2005 Sep; 7 Suppl 1():S6-12. PubMed ID: 16159420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anti-tubulin agents.
    Felip E
    Suppl Tumori; 2002; 1(4):S17-8. PubMed ID: 12415808
    [No Abstract]   [Full Text] [Related]  

  • 11. Taxanes, past, present, and future impact on non-small cell lung cancer.
    Joshi M; Liu X; Belani CP
    Anticancer Drugs; 2014 May; 25(5):571-83. PubMed ID: 24463482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ixabepilone and the narrow path to developing new cytotoxic drugs.
    Gianni L
    J Clin Oncol; 2007 Aug; 25(23):3389-91. PubMed ID: 17606970
    [No Abstract]   [Full Text] [Related]  

  • 13. Current perspectives of epothilones in breast cancer.
    Cardoso F; de Azambuja E; Lago LD
    Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epothilones: how pharmacology relates to clinical utility.
    Michaud LB
    Ann Pharmacother; 2009 Jul; 43(7):1294-309. PubMed ID: 19584389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
    Xie CY; Xu YP; Jin W; Lou LG
    Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
    Edelman MJ; Schneider CP; Tsai CM; Kim HT; Quoix E; Luft AV; Kaleta R; Mukhopadhyay P; Trifan OC; Whitaker L; Reck M
    J Clin Oncol; 2013 Jun; 31(16):1990-6. PubMed ID: 23589560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.